Gene Methylation Panel for Early Malignant Lung Nodule Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for differentiating malignant from benign lung nodules and detecting lung cancer are invasive, costly, and have low sensitivity, particularly for early-stage detection, with CT scans having high false positives and requiring skilled interpretation.

Innovation Solution

A minimally invasive method involving the measurement of DNA methylation levels of specific genes (CDO1, PTGER4, HOXA9, SHOX2, SP9, and ZNF781) in samples like blood, sputum, or saliva to detect hypermethylation, indicating malignant lung nodules and lung cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CT scan is used for lung cancer detection, then detection capability is provided, but false positive rate increases and requires skilled interpretation

Engineering Contradiction:

Improvedetection capabilityVSAvoidfalse positive rate

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent changes the detection parameter from anatomical imaging (CT scan) to molecular biomarker detection (DNA methylation patterns). By measuring methylation levels of specific genes (SHOX2, RASSF1A, O6MT, NDRG4) in liquid biopsy samples, the method achieves high detection accuracy with AUC values of 0.94-0.98, significantly reducing false positives compared to CT scanning while maintaining high sensitivity for early-stage lung cancer detection.

Inventive Principle:

Principle #35Parameter changes

2Measurement precision

If invasive methods are used for lung nodule differentiation, then diagnostic accuracy can be improved, but patient comfort and accessibility deteriorate

Engineering Contradiction:

Improvediagnostic accuracyVSAvoidpatient comfort

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent uses liquid biopsy (blood, sputum, or saliva samples) as an intermediary to obtain tumor-derived DNA without direct tissue sampling. This non-invasive approach allows measurement of gene methylation patterns that accurately differentiate malignant from benign nodules, achieving diagnostic accuracy comparable to invasive methods while significantly improving patient comfort and accessibility.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If large panels of next generation sequencing are used, then detection sensitivity can be improved, but test cost significantly increases

Engineering Contradiction:

Improvedetection sensitivityVSAvoidtest cost

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent extracts and measures only the specific methylation markers most relevant to lung cancer detection (SHOX2, RASSF1A, O6MT, NDRG4) rather than performing comprehensive genomic sequencing. This targeted approach using methylation-specific qPCR reduces test costs significantly while maintaining high detection sensitivity, making the assay economically viable for clinical practice and screening programs.

Inventive Principle:

Principle #2Taking out (Extraction)

4Reliability

If CT scan interpretation is performed, then lung nodule detection is achieved, but requirement for well-trained and experienced doctors increases

Engineering Contradiction:

Improvedetection accuracyVSAvoidskill requirement

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces the mechanical/visual interpretation process by radiologists with an automated molecular assay. The methylation detection uses standardized qPCR protocols with objective quantitative readouts, eliminating the need for subjective image interpretation skills. This substitution reduces dependency on highly trained specialists while maintaining or improving diagnostic accuracy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Provides accurate and cost-effective early detection of malignant lung nodules and lung cancer with high specificity, using non-invasive sampling methods and quantitative real-time PCR techniques.

Implementation Method 1

DNA methylation is a promising marker for the early detection of cancer because of its stability and heritability. Aberrant DNA methylation results in dysregulation of various genes and occurs in all stages of lung cancer, including initiation, growth, and metastasis.

Methodology Applied

Scientific EffectDNA methylation:

Data Source

PatentUS20250361563A1Methods, compositions, and kits for detecting malignant lung nodules and lung cancer

Publication Date: 2025.11.27 SUZHOU HUHU HEALTH TECH CO LTD

AI summary

The present disclosure provides minimally invasive methods for determining whether a lung nodule is malignant or not by measuring the methylation level of a combination of genes, including CDO1, PTGER4, HOXA9, SHOX2, SP9, and ZNF781. The disclosed methods are also able to detect lung cancer. The present disclosure also discloses polynucleotides and kits that could be used in measuring the methylation level of the CDO1, PTGER4, HOXA9, SHOX2, SP9, and ZNF781.